Renal cell carcinoma represents approximately 3% of adult malignancies and 90-95% of neoplasms arising from the kidney. Many agents that target angiogenesis (e.g., sunitinib, sorafenib, bevacizumab and pazopanib) and mTOR-targeted therapy (e.g., temsirolimus and everolimus) have been approved as first-line agents. The choice of the most suitable treatment for advanced renal cell carcinoma depends on the definition of risk. In this article, we reviewed the scientific literature identifying predictive factors on the activity/efficacy of a specific therapy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1586/era.11.63 | DOI Listing |
Publication Analysis
Top Keywords
renal cell
12
cell carcinoma
12
predictive factors
8
factors response
4
response treatment
4
treatment patients
4
patients metastatic
4
metastatic renal
4
carcinoma evidence
4
evidence renal
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!